share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募資說明書
美股SEC公告 ·  07/31 12:37

Moomoo AI 已提取核心訊息

Panbela Therapeutics, Inc. has filed a prospectus supplement on July 30, 2024, to update and supplement information related to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. This follows the original prospectus dated April 2, 2024, and is part of the registration statement on Form S-1. The common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.35 per share as of July 29, 2024. Additionally, on July 24, 2024, Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., entered into a Loan Agreement with USWM, LLC for a term loan of $1,500,000. The loan is accompanied by a Term Promissory Note and is secured by a first priority security interest in all rights, title, and interest in the Asset Purchase Agreement. The company is obligated to complete a Qualifying Financing by December 31, 2024, and a Qualifying Transaction by July 24, 2025, and may not incur additional debt or issue securities without the Lender's consent, except under limited circumstances.
Panbela Therapeutics, Inc. has filed a prospectus supplement on July 30, 2024, to update and supplement information related to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. This follows the original prospectus dated April 2, 2024, and is part of the registration statement on Form S-1. The common stock is quoted on the OTCQB under the symbol 'PBLA' with the last reported sales price being $0.35 per share as of July 29, 2024. Additionally, on July 24, 2024, Panbela Therapeutics and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., entered into a Loan Agreement with USWM, LLC for a term loan of $1,500,000. The loan is accompanied by a Term Promissory Note and is secured by a first priority security interest in all rights, title, and interest in the Asset Purchase Agreement. The company is obligated to complete a Qualifying Financing by December 31, 2024, and a Qualifying Transaction by July 24, 2025, and may not incur additional debt or issue securities without the Lender's consent, except under limited circumstances.
Panbela Therapeutics, Inc.於2024年7月30日提交了一份招股書補充說明書，以更新和補充有關發行8,750,000股普通股的信息，該普通股是之前發行的E類和F類普通股購買權的基礎。該招股書補充說明書是繼2024年4月2日的原始招股書後提交的，並且屬於S-1表格的註冊聲明的一部分。該普通股在OTCQb上的代碼是“PBLA”，截至2024年7月29日，最後報告銷售價爲每股0.35美元。此外，2024年7月24日，Panbela Therapeutics及其子公司Cancer Prevention Pharmaceuticals，Inc.與USWm，LLC簽署了一份貸款協議...展開全部
Panbela Therapeutics, Inc.於2024年7月30日提交了一份招股書補充說明書，以更新和補充有關發行8,750,000股普通股的信息，該普通股是之前發行的E類和F類普通股購買權的基礎。該招股書補充說明書是繼2024年4月2日的原始招股書後提交的，並且屬於S-1表格的註冊聲明的一部分。該普通股在OTCQb上的代碼是“PBLA”，截至2024年7月29日，最後報告銷售價爲每股0.35美元。此外，2024年7月24日，Panbela Therapeutics及其子公司Cancer Prevention Pharmaceuticals，Inc.與USWm，LLC簽署了一份貸款協議，獲得了150萬美元的期限貸款。該貸款附有一張期票，由財產購買協議的所有權、所有權和利益構成的頭等優先安全利益作擔保。該公司有義務在2024年12月31日之前完成一次符合要求的融資，直到2025年7月24日之前完成一次符合要求的交易， 若未經出借人同意，公司不得負債或發行證券，除非在有限的情況下。

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間